Page 24 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 1
35. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. Groupe d’étude des lymphomes de l’adulte (GELA). SUVmax reduction improves early prognosis value of interim positron emission tomogra- phy scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37-43.
36. Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma comparison between Deauville criteria and ∆SUVmax. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-1320.
37. Meignan M, Itti E, Gallamini A, Haioun C. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand? Leuk Lymphoma. 2009;50(11):1753-1756.
38. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50(4):527‐533.
39. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993 Sep;329(14):987-994.
40. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
41. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837- 842.
42. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380. Erratum in: J Clin Oncol. 2011;29(6):779.
43. Ruppert AS, Dixon JG, Salles GA, et al. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. Blood. 2020;135(23):2041-2048.
44. Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91(5):697‐703.
45. Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017‐2022.
46. Cheebsumon P, van Velden FH, Yaqub M, et al. Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment. J Nucl Med. 2011;52(10):1550-1558.
47. Frings V, van Velden FH, Velasquez LM, et al. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014;273(2):539-548.
48. PETRA consortium. Available from: https://petralymphoma.org/.
49. Lygature, Translation Research IT (TraIT) project. Available from: https://www.lygature.org/data- infrastructure.
50. Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase 3 trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. 2020;38(29):3377-3387.
51. HOVON imaging werkgroep. Available from: http://www.hovon.nl/werkgroepen/technische- commissies/imaging-werkgroep.html.
52. Keosys medical imaging. Available from: https://www.keosys.com/.
22